CCP
LLY icon

Corient Capital Partners’s Eli Lilly LLY Stock Holding History

Corient Capital Partners’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$14M Hold
43,239
– – 1.05% 13
2022
Q2 		$14M Sell
43,239
-1,806
-4% -$542K 1.06% 13
2022
Q1 		$12.9M Buy
45,045
+2,082
+5% +$536K 0.85% 17
2021
Q4 		$11.9M Sell
42,963
-173
-0.4% -$43.9K 0.79% 20
2021
Q3 		$9.97M Buy
43,136
+2,514
+6% +$620K 0.73% 22
2021
Q2 		$9.32M Buy
40,622
+2,795
+7% +$561K 0.68% 26
2021
Q1 		$7.07M Sell
37,827
-5,252
-12% -$1.03M 0.61% 37
2020
Q4 		$7.27M Sell
43,079
-534
-1% -$79.7K 0.73% 30
2020
Q3 		$6.46M Sell
43,613
-2,199
-5% -$340K 0.74% 28
2020
Q2 		$7.52M Buy
45,812
+5,394
+13% +$828K 0.92% 16
2020
Q1 		$5.61M Buy
40,418
+8,853
+28% +$1.22M 0.88% 24
2019
Q4 		$4.15M Buy
31,565
+2,520
+9% +$292K 0.53% 42
2019
Q3 		$3.25M Buy
29,045
+2,622
+10% +$292K 0.46% 50
2019
Q2 		$2.93M Sell
26,423
-2,928
-10% -$345K 0.45% 49
2019
Q1 		$3.81M Buy
29,351
+2,069
+8% +$252K 0.62% 31
2018
Q4 		$3.16M Sell
27,282
-10,002
-27% -$1.12M 0.56% 37
2018
Q3 		$4M Hold
37,284
– – 0.67% 28
2018
Q2 		$3.18M Sell
37,284
-18,330
-33% -$1.51M 0.56% 36
2018
Q1 		$4.3M Sell
55,614
-10,958
-16% -$882K 0.79% 27
2017
Q4 		$5.62M Buy
66,572
+2,646
+4% +$225K 0.96% 17
2017
Q3 		$5.47M Sell
63,926
-18,900
-23% -$1.55M 1.03% 15
2017
Q2 		$6.82M Sell
82,826
-1,394
-2% -$114K 1.04% 17
2017
Q1 		$7.08M Buy
84,220
+49,437
+142% +$3.96M 1.1% 12
2016
Q4 		$2.56M Sell
34,783
-42,634
-55% -$3.18M 0.45% 53
2016
Q3 		$6.21M Buy
+77,417
New +$6.2M 1.15% 10

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Corient Capital Partners's LLY Position: Q3 2022 in Review

Corient Capital Partners held its Eli Lilly (LLY) position steady in Q3 2022 at 43,239 shares worth $14M. The position accounts for 1.05% of the portfolio, ranked #13.

Corient Capital Partners first reported a position in LLY in Q3 2016 and has held it in 25 quarters since. 2,484 funds tracked by Wall St. Rank hold LLY as of Q3 2022.

  • Corient Capital Partners held 43,239 shares of Eli Lilly worth $14M as of Q3 2022.
  • Corient Capital Partners left its Eli Lilly share count unchanged in Q3 2022.
  • Eli Lilly made up 1.05% of Corient Capital Partners's portfolio in Q3 2022, its #13 holding.
  • Corient Capital Partners first reported a position in Eli Lilly in Q3 2016 and has held it in 25 quarters since.
  • 2,484 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.